Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Deferred Revenue: 2019-2025

Historic Current Deferred Revenue for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $360,000.

  • 4D Molecular Therapeutics' Current Deferred Revenue fell 72.62% to $360,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $360,000, marking a year-over-year decrease of 72.62%. This contributed to the annual value of $257,000 for FY2024, which is 5.86% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Current Deferred Revenue stood at $360,000 for Q3 2025, which was down 66.23% from $1.1 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Current Deferred Revenue's 5-year high stood at $18.8 million during Q1 2021, with a 5-year trough of $257,000 in Q4 2024.
  • Moreover, its 3-year median value for Current Deferred Revenue was $1.2 million (2023), whereas its average is $1.0 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Current Deferred Revenue crashed by 86.07% in 2023, and later grew by 7.26% in 2024.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Current Deferred Revenue stood at $5.1 million in 2021, then plummeted by 61.49% to $2.0 million in 2022, then plummeted by 86.07% to $273,000 in 2023, then declined by 5.86% to $257,000 in 2024, then crashed by 72.62% to $360,000 in 2025.
  • Its last three reported values are $360,000 in Q3 2025, $1.1 million for Q2 2025, and $866,000 during Q1 2025.